Home Biosimilar Antibodies Others CD markers Milatuzumab (Anti-CD74)
For research use only. Not for use in humans.

Milatuzumab (Anti-CD74)

Synonyms: Cd74,CLIP

Milatuzumab (Anti-CD74) is a humanized monoclonal antibody targeting CD74, a integral membrane protein. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. MW:145.5 KD.

Milatuzumab (Anti-CD74)

Quality Control

Batch: A255101 Purity: 99% Protein concentration: 4.54mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Milatuzumab (Anti-CD74) is a humanized monoclonal antibody targeting CD74, a integral membrane protein. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. MW:145.5 KD.

Product Details

CAS No. 899796-83-9
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06563804 TERMINATED Drug: S227928|Drug: Venetoclax Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)/AML; Chronic Myelomonocytic Leukemia (CMML) Servier Bio-Innovation LLC 2025-02-25 PHASE1; PHASE2
NCT03424603 COMPLETED Drug: STRO-001 B-cell Lymphoma; Non Hodgkin Lymphoma; Multiple Myeloma; Follicular Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Indolent Lymphoma; B Cells--Tumors Sutro Biopharma, Inc. 2018-02-22 PHASE1
NCT05611853 TERMINATED Drug: BN301 B-cell Lymphoma; Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma BioNova Pharmaceuticals (Shanghai) LTD. 2022-11-25 PHASE1; PHASE2
NCT00989586 COMPLETED Lymphoma Beth Christian 2009-09 PHASE1; PHASE2
NCT01663766 TERMINATED Drug: milatuzumab GVHD (Acute or Chronic); Acute Myeloid or Lymphoblastic Leukemia (AML or ALL); Myelodysplastic Syndrome; Chronic Myelogenous Leukemia (CML); Multiple Myeloma (MM); Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell); Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL) Gilead Sciences 2013-12 PHASE1
NCT01101594 TERMINATED Drug: hLL1-DOX (the doxorubicin conjugate of milatuzumab) Multiple Myeloma Gilead Sciences 2010-07 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-03-30)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.